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This chapter reviews the use of engineering and biomaterials approaches aimed at 
improving the capacity and compliance of the diseased urinary bladder.  The chapter 
introduces the normal bladder and describes the clinical background that drives the need 
for bladder tissue replacement and/or reconstruction.  It examines a variety of synthetic and 
natural matrices developed for different strategies in bladder reconstruction from both 
historic and contemporary perspectives, and provides a critical review of the results to date, 
including discussion of the steps needed to realise bladder tissue engineering in patients.  
Although progress has been made, the need for materials that offer the unique 
requirements for use in the bladder remains unmet and offers an open opportunity for 
future research champions in the fields of biomaterials, tissue engineering and regenerative 
medicine.  
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TISSUE ENGINEERING USING CERAMICS AND POLYMERS 
 Bladder Tissue Regeneration  
D. Morgante, J. Southgate 
 
1. Introduction 
1.1 The functioning urinary bladder: structure and function relationships. 
The urinary bladder is a complex, highly-compliant organ whose functions are to store 
variable volumes of urine for extended periods of time and to expel urine cyclically by the 
process of micturition.  By retaining urine at safe pressures and preventing retrograde flow, 
the bladder protects the delicate structure of the kidneys from irreversible tissue damage 
and organ failure (Thomas, 1997).  The remarkable capacity and compliance of the urinary 
bladder reflects a unique combination of biological, structural and biomechanical properties 
within the bladder wall.  Specifically, the basal tone of the detrusor smooth muscle is 
responsible for active mechanical tension, while extracellular matrix (ECM) proteins of the 
lamina propria provide compliance.  A further critical component is the urothelium: a 
specialised transitional epithelium found lining the inner surface of the bladder that forms 
the urinary barrier and contributes to accommodatory and mechanosensory (“fullness-
sensing”) functions (Birder et al., 2012).  The complexity of the 
biological:structural:functional relationships in the healthy normal bladder underpins the 
challenge of developing biomaterials that can be used, either alone or with cells, to patch, 
augment, reconstruct or even replace a diseased bladder.  There is a clear clinical need, but 
despite the bladder being the focus of many tissue engineering and biomaterials studies, the 




1.2 Features of the mammalian bladder 
The mammalian bladder wall is composed of four concentric layers: an outer single cell 
serous layer or adventitia that surrounds the three loosely arranged layers of detrusor 
smooth muscle (FIGURE 1).  Within this lies the viscoelastic collagenous connective tissue of 
the lamina propria supporting an array of cellular structures, including blood vessels, 
sensory and motor neurons.  Type I collagen is the most abundant ECM in the bladder wall, 
with the conformation and orientation of widely-distributed type III collagen considered 
implicit to healthy bladder tissue compliance (Chang et al., 1998).  The lamina propria is 
separated from the lumen-bounding urothelium by a capillary-rich proteinaceous basement 
membrane.   
Urothelium is classified as a transitional epithelium as histologically, it is transitional 
between non-stratified “simple” and stratified squamous type epithelia.  The entire urinary 
tract from the renal pelvis, through the ureters, the bladder and into the proximal urethra is 
lined by urothelium, but whilst the bladder and lower urinary tract arises embryologically 
from endoderm, the urothelium of the upper tract is mesodermally-derived (Hicks, 1975, 
Tanaka et al., 2010, Bock et al., 2014).  The development of essentially the same specialised 
epithelium from two embryological roots is unique and suggests an evolutionary convergent 
programme of gene selection for urinary barrier function in upper and lower urinary tracts. 
Morphologically, urothelium is stratified, with basement membrane-bound basal cells and 
lumen-facing superficial or “umbrella” cells interposed by intermediate cells that vary from 
three to seven layers according to the degree of bladder distension.  The urothelium is 
recognised as the least permeable (ie tightest) of all epithelia and maintains the urinary 
barrier throughout filling-voiding cycles.  The major barrier-forming adaptations are located 
in the large, frequently binucleated superficial cells, with specialised intercellular tight 
junctions maintaining the paracellular barrier (Acharya et al., 2004, Smith et al., 2015, Varley 
et al., 2006) and the transcellular barrier provided by multiple thickened plaques of 
Asymmetric Unit Membrane (AUM) embedded in the outer leaflet of the apical membrane 
(Hicks, 1965).  The AUM plaques are formed through the interactions of four uroplakin 
(“urothelium-plaque”) proteins and are a unique feature of urothelium (Olsburgh et al., 
2003, Wu et al., 2009, Yu et al., 1994).  AUM plaques are formed in the Golgi apparatus and 
transported to the apical membrane as fusiform vesicles (Tu et al., 2002), thereby providing 
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a source of membrane for accommodating the changes in urothelial surface area and 
helping to maintain a low pressure environment during bladder filling.   
For the tissue engineer, barrier function can be assessed in vitro from transepithelial 
electrical resistance and/or permeability studies (Rubenwolf and Southgate, 2011).  In 
addition, immunolabelling for urothelial differentiation-restricted antigens, such as the 
uroplakins and specialised tight junction proteins, can provide a surrogate marker of urinary 
barrier attainment – although it is important to be aware of inter-species differences 
(Chopra et al., 2008).  A failure to present objective evidence of urothelial differentiation 
and/or barrier function can lead to discrepancies in interpreting bladder tissue-engineering 
studies. 
In addition to its tight barrier function, a further notable feature of the urothelium is its 
regenerative capacity.  When examined in situ, normal adult urothelium is a mitotically-
quiescent epithelium that is able to undergo rapid proliferation in response to acute injury 
(Peyton et al., 2012, Varley et al., 2005).  A controlled study of urothelial damage in rats 
conducted by Lavelle and colleagues demonstrated recovery of transcellular and 
paracellular components of the urinary barrier within 72 hours, with intermediate cells 
undergoing rapid maturation to form differentiated superficial cells (Lavelle et al., 2002).  
The excellent regenerative and differentiation capacity of urothelium is critical to 
maintaining the urine-proofing properties of the bladder and has positive implications for 
tissue-engineering strategies.  
 
1.3 The clinical need for urinary bladder reconstruction 
A diverse range of congenital and acquired chronic benign and malignant conditions can 
result in loss of urinary bladder function that then require some form of intervention to 
provide a urinary continence mechanism.   
Incontinence is a socially-debilitating condition that affects some 400 million people 
worldwide (Irwin et al., 2011, Milsom et al., 2014).  The condition is complex, but may arise 
due to direct or indirect interruption of the nerve supply to the bladder, for example due to 
congenital conditions of myelomeningocele/spina bifida or acquired conditions, such as 
multiple sclerosis and spinal cord injury.  Other chronic benign bladder dysfunctions may be 
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consequential to vascular ischaemia caused by bladder outlet obstruction either during 
development or later in life, for example, acquired as the result of benign prostatic 
hyperplasia in older men.  The resultant smooth muscle cell hypertrophy and increased 
connective tissue deposition causes thickening of the bladder wall.  The effect on the 
biomechanics of the bladder wall is to render the bladder unstable, under high pressure, or 
lacking in capacity or compliance (German et al., 1994, Kruse et al., 1995, Watanabe et al., 
1996). Consequent clinical problems can range from mild to severe chronic urinary 
incontinence, to irreversible kidney damage caused by the bladder being forced to work at 
abnormally high pressures and leading ultimately to renal failure requiring kidney 
transplantation. 
Medical management aims to control the symptoms of bladder dysfunction with a range of 
drugs, including anti-muscarinics, alpha blockers, anti-diuretics and anti-cholinergics 
(reviewed in (Cameron, 2016)).  Intra-detrusor injection of Botulinum Toxin A has become 
increasingly used, but requires repeat administrations (Fowler et al., 2012, Leitner et al., 
2016, Utomo et al., 2014).  Sacral neuromodulation/neurostimulation may be used in 
selected cases.  However, a more permanent surgical augmentation of the bladder remains 
a clinical priority for those patients who develop a small-capacity, poorly compliant bladder, 
where intractable incontinence or pain destroys their quality of life, and/or where serious 
kidney damage is imminent (Biers et al., 2012, Cain and Rink, 2010).  
Bladder cancer is one of the top ten most common cancer types in the world, with 
approximately 550,000 new cases annually (Richters et al., 2019).  Patients requiring 
cystectomy (bladder removal) for high grade invasive bladder cancer represent a large 
group who can benefit from bladder reconstruction.  Bladder removal may also be opted for 
by patients suffering unremitting bladder pain, which includes (mostly) females with 
idiopathic interstitial cystitis and also persistent abusers of ketamine, a drug which results in 
the destruction of the urothelium (Kidger et al., 2016).  Common approaches for urinary 
diversion following cystectomy typically involve reconfiguring vascular pedicled bowel 
segments into orthotopic ileal neobladders, ileal conduit stomas or continent pouches (Stein 
and Skinner, 2006, Studer et al., 2004).  
It is notable that the urinary bladder is not an organ that can be successfully transplanted, 
reflecting the vascular/neural dependency for maintaining bladder health and function.  As 
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discussed in detail in the next section, the surgical augmentation of the bladder using bowel 
is considered the “gold standard” treatment for end-stage bladder disease, but significant 
clinical complications continue to drive research to find alternative options.  
 
1.4 Urinary bladder reconstruction – the current “gold standard” 
The most commonly performed surgical procedure for end-stage diseased bladders involves 
replacing or augmenting the bladder with a vascularised segment of the patient’s own 
gastrointestinal (GI) tract, with the aim of creating a compliant, high capacity low-pressure 
neo-bladder.  This procedure of enterocystoplasty involves isolating a segment of the GI 
tract on its vascular pedicle, detubularising it along the antimesenteric border to interrupt 
peristalsis, then reconfiguring and incorporating it into the bivalved bladder (augmentation 
cystoplasty) or as an orthotopic neobladder or conduit after cystectomy (Beier-Holgersen et 
al., 1994, Greenwell et al., 2001).  The use of vascularised or pedicled host tissue grafts to 
augment the bladder in surgical reconstruction has a long history (Thomas, 1997, Budzyn et 
al., 2019), with latest developments seeing a shift towards bladder reconstruction using 
minimally-invasive laproscopic or robotic surgery (Nimeh and Elliott, 2018).  
Despite success in augmenting bladder capacity, reducing intravesical pressures and 
improved continence, enterocystoplasty is associated with serious complications of bowel 
obstruction, mucus production, bladder calculi (stones), bladder perforation, metabolic 
acidosis and a possible increased long term risk of cancer (discussed {Khoury, 1992 
#32;Thomas, 1997; Greenwell et al., 2001; Lima et al., 2015; Budzyn et al., 2019).  As well as 
the morbidity associated with removing a section of bowel, a major issue is that gut 
epithelium is absorptive and mucus-producing in its normal function and, unlike urothelium, 
is not evolved structurally or functionally for long-term exposure to urine.   
Attempts to avoid the complications of enterocystoplasty have included the use of free 
(non-vascularised) tissue grafts using fascia, split skin grafts, placenta, peritoneum, dura 
membrane and others in autologous/syngeneic settings in rats, rabbits, sheep, dogs and pigs  
(Neuhof, 1917, Draper et al., 1952, Fishman et al., 1987, Hutschenreiter et al., 1978, Kelami 
et al., 1970).  Reported outcomes have been mixed, but include general problems of graft 
contraction and stone formation, alongside complications arising from the continued 
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normal functioning of the donor tissue (such as hair growth on skin grafts).  The use of free 
tissue grafts is far inferior to enterocystoplasty, but is useful for highlighting the importance 
of vascularised tissue integration to prevent contraction and fibrosis of implants  in the 
bladder wall.  
 
2.0  Bladder reconstruction approaches using cells, biomaterials and tissue 
engineering 
2.1 Objectives and approaches 
The ideal tissue engineered urinary bladder should mimic the full range of functions fulfilled 
by the normal healthy bladder.  During filling and voiding, the bladder undergoes dramatic 
changes in volume and is exposed to considerable mechanical forces (Korossis et al., 2009). 
Compliance of the bladder tissue is critical to accomplishing the low pressure storage of 
urine, as this protects the kidneys.  Although an attractive long-term goal, the development 
of sensory self-voiding function is beyond current objectives and in the majority of bladder 
reconstruction strategies, it is anticipated that voluntary emptying will be aided by clean 
intermittent self-catherisation (CISC), either via the urethra or via an ileal conduit stoma or 
vesicostomy, such as described (Mitrofanoff, 1980). 
The main approaches to bladder reconstruction can be categorised as biomaterials-based, 
cell-based or combined (tissue engineering) (FIGURE 2).  The former, involving implantation 
of a biomaterial, is a passive approach that relies on the regenerative capacity of the host 
bladder for full integration, whereby the material becomes cellularised and is eventually 
resorbed and replaced.  The alternative involves the active harvest (and possible in vitro 
expansion) of autologous cells from an appropriate host tissue, prior to surgical 
reimplantation, with or without a biomaterial ‘scaffold’ to provide structure.  There are 
relative advantages and disadvantages to each approach, but the ultimate cost-effective 
solution would be an “off the shelf” biomaterial.   
A major challenge with any approach is that where the underlying pathology of the host 
bladder is unresolved, neither passive functional biomaterial integration nor sourcing of 
healthy autologous cells for active tissue engineering approaches may be possible.  In this 
context, it is noteworthy that most experimental tissue-engineering models use healthy 
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animals and problems can emerge when promising experimental research approaches are 
transferred to a clinical disease setting. 
2.2 The cells 
Although not the main purpose of this review, the sourcing of healthy autologous cells is 
critical to all cell-based or tissue engineering approaches.  Adult autologous cells have 
several advantages over allogeneic cells in tissue engineering approaches, as the perfect 
genetic match excludes the need for immunosuppression.  However, where the damage to 
the bladder reflects an underlying chronic disease process, it may not be possible to identify 
and harvest sufficient healthy autologous cells and in the case of urothelial cancer patients, 
the use of autologous cells from the urinary tract may not be safe.  In such cases, alternative 
cell sources may be required for tissue engineered approaches to urinary tract 
reconstruction. 
Subramaniam and colleagues examined urothelial cells harvested from paediatric patients 
with congenital neuropathic and non-neuropathic end-stage bladder diseases 
(Subramaniam et al., 2011).  Whereas normal human urothelial cells are highly regenerative 
in vitro (Varley et al., 2005) and capable of differentiating to form a functional differentiated 
barrier urothelium (Cross et al., 2005), urothelial cells from end-stage diseased paediatric 
bladders showed reduced capacity for in vitro expansion and differentiation, indicating a 
need for alternative cell sources for engineered bladder reconstruction (Subramaniam et al., 
2011).  Given the desire to avoid life-long immunosuppression from the use of allogeneic 
cells, potential (but untested) solutions could include therapeutic modification of diseased 
cells during in vitro cell culture (eg using drugs or even CRISPR-Cas9 if a primary disease 
target or gene is known), use of a surrogate or transdifferentiated epithelium (Hustler et al., 
2018), or potentially, the directed differentiation of functional urothelium from autologous 
induced pluripotent stem (iPS) cells (reviewed (Wezel et al., 2011)). 
The challenges are even more stark when it comes to engineering complex multicellular 
tissues, such as the full bladder wall.  Simplistic approaches taken to extract and grow in 
vitro a collation of the different cells present in the diseased fibrotic and inflamed bladder 
wall (Atala et al., 2006), without any cognisance of the conditions needed to reconstitute a 
functional, healthy tissue, seem in retrospect naive and doomed to failure (Joseph et al., 




Biomaterials designed for direct or indirect contact with the human body are classified as 
medical devices under recognised International Standards (ISO 10993-1).  The generic 
features of biomaterials are extensively reviewed (Williams, 2019) and more specifically, the 
“ideal” biomaterial for urinary bladder reconstruction has been described as biodegradable 
and with mechanical properties compatible with urinary bladder function, including 
compliance (sometimes mistakingly referred to as “elasticity”) (Dahms et al., 1998, Elsawy 
and de Mel, 2017).   
Most biomaterials are prepared from polymeric materials that are either natural or 
synthetic in derivation, with a further important class being acellular matrices (ACMs) which 
are rendered from natural tissues by decellularisation.  To take each of these in turn: 
Natural extracted soluble polymers include alginate (Rowley et al., 1999), hyaluronan 
(Arimura et al., 2005), chitosan (Drewa et al., 2008), fibrin (Hafez et al., 2005, Hafez et al., 
2003) and collagen (Elbahnasy et al., 1998).  Alone these materials typically show good 
biocompatibility but poor tensile properties, as demonstrated by Elbahnasy (Elbahnasy et 
al., 1998).  Such materials have found use in various bladder reconstruction approaches, for 
example, as cell carriers (Hafez et al., 2005, Hafez et al., 2003), or in prevascularisation 
strategies (Hattori et al., 2006), whilst others have used them to produce hybrid materials in 
combination with reinforcing natural or synthetic fibres (Geutjes et al., 2006, Ajalloueian et 
al., 2014, Ajalloueian et al., 2013).   
Synthetic polymers that are biocompatible and biodegrade to produce non-toxic residues 
have been investigated for soft tissue applications and include poly(ethylene glycol) (PEG) 
(Adelow et al.), poly(lactic-co-glycolic acid) (PLGA) and poly(ε-caprolactone) (PCL) {Baker, 
2011 #66;Baker, 2009 #60}. The poly-α-esters are used commonly as the material has 
already been granted regulatory approvals for use in biomedical applications, for example as 
sutures (Pillai and Sharma, 2010).  Synthetic polymers are particularly versatile as they are 
compatible with a wide range of processing technologies, including electrospinning (Baker 
et al., 2006), phase separation (Rowlands et al., 2007), gas foaming (Mooney et al., 1996), 
particulate leaching (Baker et al., 2011, McGlohorn et al., 2004), bioprinting (Serrano-Aroca 
et al., 2018) and chemical cross-linking (Park et al., 2002).   This enables a huge variety of 
scaffolds to be created in knitted, felted or fabricated in other configurations with different 
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porosities, shapes and other features aimed at facilitating engraftment. Cell adherence is 
often used as an in vitro measure of biocompatibility, but there is a fundamental difference 
between 2D cell adherence to a substrate and the true 3D cell:cell and cell:matrix 
interactions that occur within a tissue (Baker et al., 2006).  The production of nanofibrous 
scaffolds to mimic the 3D architectural form and scale of the tissue matrix has been 
attempted with synthetic polymers using three main fabrication techniques: 
electrospinning, molecular self-assembly and thermally-induced phase separation 
(Holzwarth and Ma, 2011, Asadian et al., 2020). In one study, electrospun scaffolds aimed at 
mimicking the scale and alignment of ECM fibres were predicted to create favourable 
conditions for cell:cell interactions for bladder smooth muscle engineering  (Baker and 
Southgate, 2008); an approach tested by others in vivo and with partial success reported 
(Shakhssalim et al., 2017).   
Typically, biomaterials are characterised by quantifiable physical properties such as pore 
size and interconnectivity, and chemical properties, including degradation rate and surface 
chemistry.  Biomechanical properties such as stiffness are known to influence cell 
phenotype and tissue function, but any relationships are generally empirical. For example, 
PCL foams of 85-88% porosity and 35μm pore diameter produced by emulsion freeze-drying 
had a storage modulus that better approximated native bladder than equivalent foams 
constructed using PLGA. Cells grown on these different foams in vitro showed altered 
characteristics suggestive of different growth and contractile states (Baker et al., 2009).  
Nevertheless, it is poorly understood how to fine tune biomaterial properties to promote or 
enable particular biological responses, such as enhanced cellular and vascular engraftment 
or tissue-specific development, differentiation and function.   
Discrepancies may also exist between in vitro and in vivo performances.  For example, a 
porous, non-functionalised synthetic biomaterial generated by leaching sintered polystyrene 
spheres from a poly(ε-caprolactone) matrix showed limited propensity for cell infiltration in 
vitro, but was found to promote a strong stromal and angiogenic response in vivo (Baker et 
al., 2011), possibly due to architectural features such as “sweet spot” pore size (Ratner, 
2016). 
It is possible to functionalise polymer scaffolds, including nanofibrous scaffolds, by 
absorption, surface adsorption, chemical crosslinking or the indirect tethering of specific 
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growth and other bioactive factors, with the intent of enhancing biological behaviours from 
angiogenesis through to more complex behaviours (reviewed (Chen et al., 2010, Asadian et 
al., 2020)).  The modification of surfaces by the covalent attachment of heparin offers one 
useful “biomimetic” approach as many growth factors are heparin-binding and tether 
naturally to heparin in their most natural, bioactive conformation (Rohman et al., 2009, 
Roelofs et al., 2018).   
Natural acellular matrices (ACM) represent the insoluble matrix that remains after tissue 
decellularisation (Crapo et al., 2011, Keane et al., 2015).  ACMs retain collagen, fibronectin, 
laminin, glycosaminoglycans and sequestered bioactive factors in original, tissue-specific 
architectures (reviewed (Davis et al., 2010, Gilbert et al., 2006, Marcal et al., 2012)).  Such 
matrices are therefore predicted to provide a framework for homologous tissue 
regeneration following cell infiltration and remodelling by the recipient’s own cells (Badylak, 
2002).  Nevertheless, it is important to appreciate that tissue structure has no blueprint, but 
is an emergent property of development.  This raises questions about how effectively an 
implanted ACM will be remodelled into a functional tissue in vivo, particularly when 
implanted into a diseased tissue setting.  Nevertheless, bladder ACM retains excellent 
compliance [FIGURE 3] and shows tissue- and immuno-compatibility, even when used in an 
allo- or cross-species setting.  For example, in organ culture studies where human urinary 
tract tissue was combined with a porcine bladder-derived ACM (Bolland et al., 2007), 
infiltrating innate cells were polarised by bladder ACM to a tissue-integrative non-
inflammatory M2 phenotype (Bullers et al., 2014).  This presumably is a reflection of the 
high degree of conservation of the ECM between mammalian species.   
ACMs have been reported to display batch and other variabilities (Ashley et al., 2010, Kropp 
et al., 2004) and/or carry risk of adverse reactions if there is inadequate removal of 
immunoreactive host material (Feil et al., 2006, Keane et al., 2012) or other potential 
xenopathological agents.  Badylak’s group from Pittsburgh proposed three minimum criteria 
for satisfactory decellularisation: 1) no visible nuclei upon histological evaluation using H&E 
and DNA stains; 2) the double stranded DNA (dsDNA) content to be <200 base pair fragment 
length; and 3) the amount of double-stranded DNA to be <50 ng per mg of dry weight of the 
material (Keane et al., 2015). 
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3. Review of bladder tissue engineering studies  
Enterocystoplasty was first described in a canine model in 1888 and then in man a year 
later, but it was not until the mid-twentieth century that the technique became popular for 
the treatment of the contracted, tuberculous bladder.  Stomach (gastrocystoplasty), small 
intestine (ileocystoplasty) and large intestine (colocystoplasty) have all been used as the 
vascularised reconstructing segment, with ileocystoplasty the most commonly performed 
procedure in the UK (Thomas, 1997).   
3.1 Adaptations to enterocystoplasty  
Given that the major side effects of enterocystoplasty are caused by the long-term exposure 
of the bowel mucosa to urine, a logical solution is to remove the bowel epithelium and leave 
the smooth muscle surface facing the lumen (seromuscular enterocystoplasty using 
demucosalised intestinal tissue).  Performed experimentally in large animal (canine, porcine 
and bovine) surgical models, the latter approach has resulted in graft contraction, fibrosis, 
shrinkage, diverticulation and metaplasia, irrespective of which side of the bowel wall faces 
the lumen(Aktug et al., 2001, Clementson Kockum et al., 1999, Fraser et al., 2004, Hafez et 
al., 2005, Motley et al., 1990, Salle et al., 1990).  These problems are thought to reflect 
severe inflammation secondary to urine exposure, infection of the graft and/or to ischemia 
or damage to the bowel segment during surgical dissection.  There is some evidence that 
fibrosis may be avoided by retaining an intravesical silicone balloon for 2 weeks post-
augmentation (Vilar et al., 2004), or more naturally, by finding strategies to cover the 
augmenting graft with urothelium (Aktug et al., 2001, Hafez et al., 2005, Turner et al., 2011).  
Hafez and colleagues developed an aerosol transfer technique using suspensions of 
disaggregated bladder tissue cells in a fibrin glue (Hafez et al., 2003, Hafez et al., 2005).  
Autologous urothelial cells with or without smooth muscle cells, isolated at 
hemicystectomy, were sprayed onto deepithelialised colon and then incorporated into the 
remaining bladder.  Studies assessed after 6 weeks (Hafez et al., 2005) and 6 months (Hidas 
et al., 2015) were described as resulting in a stratified, multi-layered uroplakin-positive 
urothelium atop of a bladder or colonic smooth muscle submucosa, respectively, and an 
absence of inflammation.  An important limitation of this approach is the lack of “spare” 
healthy bladder tissue to provide adequate numbers cells of sufficient quality for the 
procedure.   
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Composite cystoplasty aims to get round the dearth of urothelium by expanding urothelial 
cells in vitro from small cyctoscopic biopsies, prior to reimplantation as cell sheets onto a 
pedicled de-epithelialised host smooth muscle segment used to augment the bladder.  This 
approach exploits the regenerative nature of urothelium.  First described in concept (Hutton 
et al., 1993), the approach was tested in a porcine in vivo model, first with sheets of 
undifferentiated urothelial cells (Fraser et al., 2004) and later with functional barrier-
differentiated urothelial cell sheets (Turner et al., 2011).  In each case, a PLGA (Vicryl™) 
mesh was used as a vehicle to transport the polarised urothelial cell sheets from cell culture 
to surgical site where it acted to protect the apical surface and facilitate integration of the 
basal surface with the host tissue.  The latter study showed that implanting a differentiated 
(ie functional barrier) urothelial cell sheet prevented the inflammation seen when non-
differentiated urothelial cell sheets had been used (Turner et al., 2011). 
Neither the Hafez nor Fraser/Turner approaches described above have yet been reported to 
progress to clinical trials.  Remaining challenges include the nature of diseased bladders 
requiring reconstruction, as features of the pathology, such as hypoxia (Radford et al., 2019) 
may impact on the tissue engineering potential of available autologous cells (Subramaniam 
et al., 2011) (and see section 2.2).  However, a strategy that uses a preformed innervated 
and vascularised smooth muscle host tissue and only requires a single engineered tissue 
component, the urothelial urinary barrier, is less ambitious than attempting to engineer the 
entire bladder wall.  
3.2 Bladder tissue engineering – the “Full Monty” 
A number of investigators have described tissue engineering of the full bladder wall 
following subtotal (80%) cystectomy. 
Atala and colleagues grew, then seeded autologous cells from the stroma and urothelium 
onto outer and inner surfaces of PGA mesh moulded into the shape of a bladder and coated 
with PLGA, (Oberpenning et al., 1999).  The constructs were implanted in vivo onto a 
bladder base remaining after trigone-sparing cystectomy in dogs.  Once coated with fibrin 
glue, the construct was wrapped with omentum and the animals monitored for up to 11 
months.  There were no reported complications and at three months, the polymer had 
degraded, leaving a vascularised, innervated tissue composed of organised smooth muscle 
bundles and a stratified urothelium, which was positive with antibodies against AUM.  A 
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similar approach and two year findings were reported by Jayo and colleagues, who seeded a 
PLGA-based biodegradable synthetic polymer matrix with autologous urothelial and smooth 
muscle cells in a 80% sub-total cystectomy canine model.  The constructs were reported to 
grow during skeletal maturation of the young animals (Jayo et al., 2008).  The use of an 
omentum wrap appears to have been a critical step in both the Oberpenning and Jayo 
studies. 
Atala and colleagues moved from their healthy canine model to test their approach in nine 
patients with severely neuropathic bladders (Atala et al., 2006).  Collagen-only and collagen-
PGA hybrid scaffolds were seeded with autologous stromal and urothelial cells and 
implanted.  Three patients had a collagen-only implant, one had a collagen-only implant 
with an omental wrap and three patients had a collagen-PGA hybrid scaffold with an 
omental wrap.  Two patients were lost to follow up and one patient with a collagen-only 
implant underwent conventional augmentation because of progressively rising intravesical 
pressures.  The remaining patients were followed up annually for up to five years, although 
only four had investigations in the fifth year.  The results showed minimal or modest 
increases in capacity and compliance of the bladders, with the best outcome in patients 
receiving cell-seeded collagen-coated PGA scaffolds that were wrapped in omentum as a 
vascular bed.  The new bladder tissue was described as having a normal structure, with 
smooth muscle and stratified urothelium; however, the differentiation status of the 
urothelium was not reported.  A follow up clinical trial was halted due to unacceptable 
adverse events (Joseph et al., 2014) and the approach heavily criticised as simplistic in an 
accompanying Editorial (Farhat, 2014).  
3.3 ACM and other collagen-based matrices.  
The two ACMs most studied for their potential application in bladder reconstruction are 
porcine small intestinal submucosa (SIS) and bladder acellular matrix (BAM), both of which 
were tested extensively in vitro and in preclinical surgical models before entering clinical 
trials (reviewed by (Kropp, 1998, Song et al., 2014, Pokrywczynska et al., 2015)).   
SIS is prepared from porcine small intestine after mechanical delamination of the bowel wall 
to leave the collagen- and elastin-rich submucosal layer (Badylak et al., 1989).  SIS has been 
variously employed as matrix alone, seeded with cells, or used in combination with synthetic 
or natural biomaterials.  However, despite extensive and often promising in vitro and in vivo 
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studies (not reviewed here), results from clinical studies have reported unsatisfactory 
results in terms of bladder capacity, compliance, muscle regeneration and continence 
(Caione et al., 2012, Schaefer et al., 2013, Zhang and Liao, 2019). 
BAM was first described in 1975 (Meezan et al., 1975).  Despite initial promising results in 
small animals, transfer to a larger porcine model gave less favourable results, with 
contracture and failure of recellularization in the central areas of the implanted graft (Brown 
et al., 2002, Reddy et al., 2000).  Further studies with cell-seeded BAM in a canine model 
(Yoo et al., 1998) provided proof of concept for a pilot human clinical study (Atala et al., 
2006).  However, the patients showed limited benefit, with deterioration in bladder 
capacity, compliance and leak point pressures.  
Considering the major lessons to be learned from the SIS and BAM experiences, it is clear 
that graft size is one issue, and scaling from small to clinically-relevant implant sizes can 
overwhelm any regenerative properties inherent in a natural graft material.  In rat models, 
for example,  graft size is necessarily small (<0.5 cm2) compared to a 4 x 4 cm2 acellular 
dermal patch incorporated into a pig bladder (Akbal et al., 2006).  A second issue, 
mentioned above, is that most surgical models involve healthy animals, whereas attempts 
to use disease models almost invariably fail (Zhang et al., 2006, Akbal et al., 2006), which 
leaves a wide gap when translating research findings to a clinical population.  A final issue 
relates to the processing of natural materials as they transfer from research to more 
commercial clinical settings.  For example, required terminal sterilisation procedures can 
have a profound negative effect on the properties of natural acellular matrices, leading to 
inhibition of cellular infiltration (Badylak, 2002, Bullers et al., 2014, Kimuli et al., 2004).  
Thus, despite early promise, ACMs have encountered problems of translation that have yet 
to be overcome.  
3.4 Natural, synthetic and hybrid biomaterials 
A number of studies have attempted to use collagen-based materials, recognising that as 
the major structural protein in the body, collagen is largely responsible for the strength and 
conformability of natural materials.  Such studies have included the use of commercial 
collagen-based products such as INTEGRA™ (preparation of collagen type 1 and chondroitin-
6-sulphate) (Parshotam Kumar et al., 2010) and OptiMaix (Leonhauser et al., 2017).  Other 
groups have attempted to enhance the natural biocompatibility of collagen with growth 
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factors including VEGF, FGF2 or HBEGF (Roelofs et al., 2018), or insulin-like growth factor 
(Vardar et al., 2016).  Whereas the Roelofs study showed no advantage of added growth 
factors, the Vardar study reported hypertrophy of the constructed urothelium, with a 
potential risk of urinary outlet obstruction.  Overall, studies using collagen scaffolds, 
whether enhanced or not by cells or bioactive factors, have not yielded results that have led 
to clinical translation.  
Synthetic materials should offer advantages over natural biomaterials in terms of 
reproducibility of composition, lower production costs and industrial scale up.  Chemical 
inertness alone is no guarantee of successful bladder integration and implantation of 
synthetic materials (including plastics, polyvinyl sponge and polytetrafluoroethylene 
(Teflon™)) into the bladder have all met with failure to the point that the use of such 
materials is considered obsolete.  As described in section 3.2, the use of synthetic materials 
in combination with cells from healthy animals has had some reported success in 
conjunction with the use of a vascularising omentum, but any potential was lost during 
translation to a diseased bladder patient population.  
 
4. Conclusions and future trends 
Reconstruction of the urinary bladder is carried out when conservative and medical 
therapies have failed to alleviate the debilitating symptoms of a small, non-compliant or 
diseased bladder.  Surgical reconstruction with intestine (enterocystoplasty) remains the 
“gold standard” approach for providing patients with a continent, kidney-protecting 
reservoir, nonwithstanding the significant consequences of using an absorptive, mucus-
producing bowel epithelium in place of a urothelial urinary barrier.  For the present, 
improvements over enterocystoplasty via any biomaterials or tissue engineering route 
appears to have met an impasse. This failure to find a practical solution for bladder 
augmentation/reconstruction is disappointing given that it was back in 2006 when it was 
first announced that tissue engineered bladder replacement in children was a reality (Atala 
et al., 2006).  The time since has seen the less-publicised failure of the Tengion®-sponsored 
clinical trial (Joseph et al., 2014) and reduced interest/funding for a clinical problem 
perceived by many to have been solved.  So where do we go from here?  
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Substitution of the bowel epithelium by autologous urothelium remains an attractive 
strategy as it overcomes any need to engineer the complex vascularised smooth muscle 
component of the bladder wall.  However, given the costs of personalised cell therapy, it is 
likely that a biomaterials approach would offer the more attractive cost-effective solution.   
Clinical practice is also likely to favour a cell-free reconstructive approach incorporating 
biomaterials alone.  This will rely on developing suitable scaffold materials that both harness 
a tissue integration response and match the physical requirements of the bladder for 
compliance.  These properties are currently most promisingly realised by bladder wall ACM, 
but understanding how integral matrix proteins such as collagens type I and III interact to 
develop the unique physical properties of the bladder matrix may facilitate the 
development of new nature-inspired materials. Finally, the route from laboratory to patient 
needs to be signposted to help promising novel products or strategies overcome the 
translational hurdle, particularly when transferring from a normal to disease state.  One 
possibility is that modulation of the disease environment may provide a more conducive 
platform for rejuvenated cells to work with ACMs or nature-inspired scaffolds towards 
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FIGURE 1.  Transverse section through the porcine bladder stained with haematoxylin and 










FIGURE 2. Strategies for bladder reconstruction can be categorised as biomaterials-based, 
cell-based or combined tissue engineering approach, where the generated tissue construct 
may be maintained and even functionally conditioned in a bioreactor prior to implantation 
in vivo.  Notably, in some studies, the in vitro bioreactor may be substituted with an in vivo 







FIGURE 3.  Macroscopic appearance of a natural matrix derived from porcine bladder by 
decellularisation, as described (Bolland et al., 2007).  Decellularisation of the full thickness 
wall was achieved after distension and immersion of the intact bladder in a sequential series 
of sterile extraction buffers, including detergents and DNAse to lyse and remove cell 
components and render the tissue acellular.  At the end of the procedure, the decellularised 
bladder is dissected open to present the biomaterial as a flattened sheet. The biomaterial 
retains many useful properties of the bladder wall including strength and compliance. Scale 
bar 1cm. 
 
 
